Основная статистика
| LEI | 254900W0P77PQ6B8OY50 |
| CIK | 1641281 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bolt Biotherapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biothe |
|
| August 14, 2025 |
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study • Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, CA, August 14, 2025 – Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutic |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 6, 2025 |
Certificate of Amendment of the Amended and Restated Certificate of Incorporation. EXHIBIT 3.1 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Bolt Biotherapeutics, Inc. Bolt Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies that: First: The name of this corporation is Bolt Biotherapeutics, Inc. (the “Company”). Second: The date of filing o |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 4, 2025 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 28, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Bioth |
|
| May 12, 2025 |
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update • BDC-4182 Phase 1 dose-escalation study now open for enrollment • BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity • Bolt is running a partnering process to advance d |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 16, 2025 |
AMENDED AND RESTATED BYLAWS OF Bolt Biotherapeutics, INC. (A DELAWARE CORPORATION) EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF Bolt Biotherapeutics, INC. (A DELAWARE CORPORATION) BYLAWS OF Bolt Biotherapeutics, INC. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. Section 2. Other Offices. The corporation may also have and maintain an office or |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 24, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 24, 2025 As filed with the U.S. Securities and Exchange Commission on March 24, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-2804636 (State or other jurisdiction of Incorporation or organization) |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-399 |
|
| March 24, 2025 |
BOLT BIOTHERAPEUTICS, INC. INSIDER TRADING POLICY APPROVED BY THE BOARD OF DIRECTORS JANUARY 14, 2021 INTRODUCTION This policy determines acceptable transactions in the securities of Bolt Biotherapeutics, Inc. (the “Company” or “Bolt”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important informati |
|
| March 24, 2025 |
Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update • BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 • BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter 2025 • Cash balance of $70.2 mill |
|
| March 24, 2025 |
Subsidiaries of the Registrant BOLT BIOTHERAPEUTICS, INC. The following is a list of subsidiaries of the Company as of December 31, 2024, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. SUBSIDIARY (Name under which subsidiary does business) STATE OR OTHER JURISDICTION OF CORPORATION OR ORGANIZATION Bolt Biotherapeutics Australia PTY LTD Australia |
|
| March 24, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bolt Biotherapeutics, Inc. |
|
| January 3, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 02, 2025 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 14, 2024 |
BOLT / Bolt Biotherapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2427061d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Shar |
|
| November 12, 2024 |
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update • Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers • Presented updated preclinical activity of BDC-4182 and key learnings from Phase 1 dose-escalation trial of BDC-1001 at the SITC 39th Annual Meeting • BDC-4182 on |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt B |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biothe |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2024 |
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers • Abstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting • Cash balance of $97.5 million |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 14, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
Consulting Agreement by and between the Registrant and Edith Perez, dated May 13, 2024 Exhibit 10.2 BOLT BIOTHERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into as of May 13, 2024 and will be effective as of July 15, 2024 (the “Effective Date”) between Bolt Biotherapeutics, Inc. (“Company”) and Edith A. Perez, M.D. (“Consultant”). Company desires to retain Consultant to perform certain consulting activities as described below, and Consultan |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Bioth |
|
| May 14, 2024 |
Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team • Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation BoltbodyTM ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2 • Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) an |
|
| May 14, 2024 |
Consulting Agreement by and between the Registrant and Randall C. Schatzman, dated May 13, 2024 Exhibit 10.1 BOLT BIOTHERAPEUTICS, INC. CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into as of May 13, 2024 and will be effective as of July 15, 2024 (the “Effective Date”) between Bolt Biotherapeutics, Inc. (“Company”) and Randall C. Schatzman, Ph.D. (“Consultant”). Company desires to retain Consultant to perform certain consulting activities as described below, and Co |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 21, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97.1 Bolt biotherapeutics, inc. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Po |
|
| March 21, 2024 |
As filed with the U.S. Securities and Exchange Commission on March 21, 2024 As filed with the U.S. Securities and Exchange Commission on March 21, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-2804636 (State or other jurisdiction of Incorporation or organization) |
|
| March 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bolt Biotherapeutics, Inc. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-399 |
|
| March 21, 2024 |
Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update – BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 20 |
|
| February 14, 2024 |
BOLT / Bolt Biotherapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243573d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Share |
|
| February 14, 2024 |
BOLT / Bolt Biotherapeutics, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO.1 Passive Investment SC 13G/A 1 z111241sc13ga1.htm AMENDMENT NO.1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check |
|
| February 13, 2024 |
SC 13G/A 1 ea193541-13ga1vivo8bolt.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) December 31, 2023 (Date of Event which |
|
| February 12, 2024 |
SC 13D/A 1 d773403dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 097702 104 (CUSIP Number) Louis Rambo Proskauer Rose LLP 1001 Pennsylvania Avenue, NW Suite 600 South Washington, DC 20 |
|
| November 9, 2023 |
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update – BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical efficacy and longer durability; FDA Orphan Drug Designation granted for t |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt B |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biothe |
|
| August 7, 2023 |
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update – First patients dosed in the BDC-1001 Phase 2 program – BDC-1001 Phase 1 data presented at ASCO 2023 demonstrated favorable safety profile and encouraging efficacy as a monotherapy and in combination with nivolumab in HER2-expressing tumors – BDC-3042 received IND clearance; clinical trial |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update – Comprehensive BDC-1001 clinical safety and efficacy data as a single agent and in combination with nivolumab, including RP2D, to be presented at ASCO 2023 – BDC-1001 Phase 2 program expected to initiate in 2023 in HER2+ colorectal, endometrial, gastroesophageal, and breast cancer – Cash ba |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Bioth |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 20, 2023 |
BOLT / Bolt Biotherapeutics Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 20, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of Bolt Biotherapeutics, Inc. and further agree to the filing of this agreement as an exhibit |
|
| March 29, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 29, 2023 As filed with the U.S. Securities and Exchange Commission on March 29, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-2804636 (State or other jurisdiction of Incorporation or organization) |
|
| March 29, 2023 |
Exhibit 99.2 Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies BDC-1001 elicited objective clinical responses, including multiple PRs and long-term stable disease, across a diverse set of solid tumor types in monotherapy and in combination with nivolumab Data support sel |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents n UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 29, 2023 |
Amended and Restated Severance and Change in Control Plan. Exhibit 10.24 Exhibit 10.24 BOLT BIOTHERAPEUTICS, INC. SEVERANCE AND CHANGE IN CONTROL PLAN Modified BY THE Compensation Committee: 12/5/2022 Section 1. INTRODUCTION. The Bolt Biotherapeutics, Inc. Severance and Change in Control Plan (the “Plan”) was established on February 5, 2021. The purpose of the Plan is to provide for the payment of severance and/or Change in Control (as defined below) bene |
|
| March 29, 2023 |
Exhibit 10.25 Exhibit 10.25 FIRST Amendment to LEASE AGREEMENT This First Amendment to Lease Agreement (this “First Amendment”) is made as of November 7, 2022 by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”) and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”). R E C I T A L S A. Landlord and Tenant entered into that certain Lease dated August |
|
| March 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bolt Biotherapeutics, Inc. |
|
| March 29, 2023 |
Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update – Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety – BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in |
|
| February 14, 2023 |
BOLT / Bolt Biotherapeutics Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233236-5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (the “Share |
|
| February 13, 2023 |
BOLT / Bolt Biotherapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992731713g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| January 4, 2023 |
BOLT / Bolt Biotherapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702 104 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. S |
|
| December 28, 2022 |
BOLT / Bolt Biotherapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702 104 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 10, 2022 |
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update ? BDC-1001 dose-escalation clinical trial on track to complete recruitment by year-end 2022 ? BDC-3042 on track to enter the clinic in 2023; new preclinical data at SITC 2022 ? Cash balance of $209. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt B |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 30, 2022 |
BOLT / Bolt Biotherapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702 104 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biothe |
|
| August 10, 2022 |
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update ? BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year ? New portfolio prioritization and capital allocation strategy extends expected cash runway by an additional two years ? Cash balance of $223. |
|
| August 10, 2022 |
Clarification Letter dated April 27, 2022 between the Registrant and EirGenix, Inc. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 15, 2022 |
BOLT / Bolt Biotherapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702 104 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 16, 2022 |
BOLT / Bolt Biotherapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2215244d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) May 16, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| May 12, 2022 |
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights ? BDC-1001 monotherapy and OPDIVO? combination trials progressing toward data readouts in second half of 2022 ? Cash balance of $246. |
|
| May 12, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Bioth |
|
| April 28, 2022 |
DEFA14A 1 boltdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 7, 2022 |
424B5 1 d341935d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263994 PROSPECTUS $ 75,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.00001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell s |
|
| April 5, 2022 |
April 5, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Abby Adams Re: Bolt Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-263994 Acceleration Request Requested Date: April 7, 2022 Requested Time: 4:00 PM Eastern Daylight Time Ladies and Gentlemen: In accordance with Rule 461 under th |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Bolt Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 30, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 BOLT BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF BOLT BIOTHERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organiz |
|
| March 30, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 30, 2022 As filed with the U.S. Securities and Exchange Commission on March 30, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-2804636 (State or other jurisdiction of Incorporation or organization) |
|
| March 30, 2022 |
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights ? BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO? (nivolumab) progressing well ? Preclinical data on multiple pipeline programs will be presented at AACR 2022, including BDC-2034, BDC-3042, and a PD-L1 ISAC ? Cash balance of $272 million expected to fund key milestones and operations into 2024 REDWOOD CITY, CA, March 30, 2022 ? Bolt Biotherapeutics, Inc. |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-399 |
|
| March 30, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Bolt Biotherapeutics, Inc. |
|
| March 30, 2022 |
Sales Agreement, by and between the Registrant and Cowen and Company, LLC dated March 30, 2022. Exhibit 1.2 BOLT BIOTHERAPEUTICS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT March 30, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Bolt Biotherapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during t |
|
| March 30, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 BOLT BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF BOLT BIOTHERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organiz |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
Exhibit 4.4 BOLT BIOTHERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 |
|
| March 30, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 BOLT BIOTHERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED As OF BOLT BIOTHERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and ex |
|
| March 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bolt Biotherapeutics, Inc. |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 01, 2022 Bolt Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 4, 2022 |
Consulting Agreement by and between the Registrant and David Dornan, Ph.D., dated March 3, 2022. Exhibit 10.1 BOLT BIOTHERAPEUTICS, INC. CONSULTING AGREEMENT Effective Date: March 3, 2022 This Consulting Agreement (the ?Agreement?) is made as of the Effective Date set forth above by and between Bolt Biotherapeutics, Inc., a Delaware corporation (?Client?) and the consultant named on the signature page hereto (?Consultant?). The Company and Consultant acknowledge and agree that the Consultant? |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Bolt BioTherapeutics Inc (Name of Issuer) Common Stock, $0.00001 par value per share (the ?Shares?) (Title of Class of Securities) 09770210 |
|
| January 25, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 6, 2021 |
Exhibit 99.1 Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021 Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo? on target to initiate by year end 2021 Live conference call and w |
|
| December 6, 2021 |
BDC-1001 Interim Clinical Data ESMO Immuno-Oncology 2021 December 2021 1 Exhibit 99. |
|
| December 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 29, 2021 |
BOLT / Bolt Biotherapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 22, 2021 |
BOLT / Bolt Biotherapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702 104 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 9, 2021 |
Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights ?BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021 ?Strong cash position of $295.5 million expected to fund operations through the end of 2023 REDWOOD CITY, CA, November 9, 2021 ? Bolt Bi |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt B |
|
| August 13, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 097702 104 (CUSIP Number) Louis Rambo Proskauer Rose LLP 1001 Pennsylvania Avenue, NW Suite 600 South Washington, DC 20004-2533 (202).416.6878 Robert Hopfner |
|
| August 13, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| August 12, 2021 |
Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights ? BDC-1001 Phase 1/2 trial in HER2-expressing solid tumors on track for data update in 2H 2021? ? Announced R&D collaboration with Genmab to develop multiple bispecific ISACs for treatment of cancer ? ? Ended second quarter 2021 with strong cash position of $310.9 million ? REDWOOD CITY |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Biothe |
|
| June 2, 2021 |
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration Exhibit 99.1 Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration Media Release ? Collaboration to discover and evaluate novel product concepts based on the combination of Genmab?s antibodies and bispecific antibody technologies with Bolt?s proprietary immune-stimulating antibody conjugate (ISAC) platform ? Companies intend to develop multiple bispecific ISACs ? |
|
| June 2, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39988 Bolt Bioth |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 13, 2021 |
Exhibit 99.1 Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights ? Strong cash position of $302.9 million as of March 31, 2021 expected to deliver key value-creating milestones and fund operations into 2023 ? ? Upsized IPO in February 2021 raised $264.5 million in gross proceeds ? ? Lead program, BDC-1001, Phase 1/2 trial advancing on track with trial |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) April 1, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| April 7, 2021 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of April 07, 2021, is by and among RA Capital Management, L. |
|
| March 31, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-399 |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 31, 2021 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, $0.00001 par value per share (?Common Stock?) of Bolt Biotherapeutics, Inc. (the ?Company,? ?we,? ?our,? or ?us?), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Ac |
|
| March 31, 2021 |
Exhibit 99.1 Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights - Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising ? - Advanced first-in-class Boltbody? ISAC into the clinic in 2020 and continued to expand pipeline of pioneering imm |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Bolt Biotherapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) February 9, 2021 Date of Event Which Requires Filing of the Statement Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 19, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Bolt Biotherapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of th |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702104 (CUSIP Number) February 9, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 17, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 097702 104 (CUSIP Number) Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002 (Name, Address an |
|
| February 17, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 097702104 (CUSIP Number) Nathalie Auber Sofinnova Investment |
|
| February 11, 2021 |
Exhibit 99.1 Execution Version , 2020 Morgan Stanley & Co. LLC SVB Leerink LLC As Representatives of the several Underwriters listed on Schedule I to the Underwriting Agreement referred to below c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, California 94111 Ladies and Gentlemen: The undersigned understands that Mo |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bolt Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 097702 104 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Ken |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39988 47-2804636 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 9, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. EX-3.1 2 d68629dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BOLT BIOTHERAPEUTICS, INC. Randall C. Schatzman, Ph.D. hereby certifies that: ONE: The original name of this corporation is Bolt Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was January 22, 2 |
|
| February 5, 2021 |
February 5, 2021 (File No. 333-252815) S-8 As filed with the U.S. Securities and Exchange Commission on February 5, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-2804636 (State or other jurisdiction of Incorporation or organiza |
|
| February 5, 2021 |
11,500,000 Shares COMMON STOCK 424B4 Table of Contents Index to Financial Statements Filed Pursuant to Rule 424(b)(4) Registration Nos. |
|
| February 4, 2021 |
S-1MEF As filed with the U.S. Securities and Exchange Commission on February 4, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 47-2804636 (State or Other Jurisdiction of Incorporation or |
|
| February 3, 2021 |
Amendment No 2 to Form S-1 Table of Contents Index to Financial Statements As filed with the U. |
|
| February 2, 2021 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BOLT BIOTHERAPEUTICS, INC. |
|
| February 2, 2021 |
BOLT BIOTHERAPEUTICS, INC. 900 Chesapeake Drive Redwood City, California 94063 February 2, 2021 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 ATTN: Mr. Donald Field Ms. Sonia Bednarowski Ms. Kristin Lochhead Mr. Daniel Gordon RE: Bolt Biotherapeutics, Inc. Registration Statement on Form S-1 File No. 333-252136 |
|
| February 2, 2021 |
Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 SVB Leerink LLC 255 California Street, 12th Floor San Francisco, California 94111 February 2, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Bolt Biotherapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-252136) Request for A |
|
| February 1, 2021 |
2021 Employee Stock Purchase Plan. EX-10.7 Exhibit 10.7 BOLT BIOTHERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 22, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 25, 2021 1. GENERAL (a) Purpose. The Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of Employees and to provide incentives for such persons to exert maximum effor |
|
| February 1, 2021 |
Amendment No 1 to Form S-1 Table of Contents Index to Financial Statements As filed with the U. |
|
| February 1, 2021 |
EX-10.4 Exhibit 10.4 BOLT BIOTHERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JANUARY 22, 2021 APPROVED BY THE STOCKHOLDERS: JANUARY 25, 2021 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 6 6. ADJUSTMENTS UPON C |
|
| February 1, 2021 |
2015 Equity Incentive Plan, as amended. EX-10.2 Exhibit 10.2 BOLT BIOTHERAPEUTICS, INC. (FKA BOLT THERAPEUTICS, INC.) AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN ORIGINAL PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 20, 2015 ORIGINAL PLAN APPROVED BY THE STOCKHOLDERS: APRIL 20, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 17, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE STOCKHOLDERS: SEPTEMBER 21, 20 |
|
| February 1, 2021 |
EX-10.6 Exhibit 10.6 BOLT BIOTHERAPEUTICS, INC. RSU AWARD GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Bolt Biotherapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and |
|
| February 1, 2021 |
EX-10.5 Exhibit 10.5 BOLT BIOTHERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT As reflected by your Stock Option Grant Notice (“Grant Notice”) Bolt Biotherapeutics, Inc. (the “Company”) has granted you an option under its 2021 Equity Incentive Plan (the “Plan”) to purchase a number of shares of Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Cap |
|
| February 1, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BOLT BIOTHERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Bolt Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIF |
|
| February 1, 2021 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [•] Shares BOLT BIOTHERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENT [•], 2021 [•], 2021 Morgan Stanley & Co. LLC SVB Leerink LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, California 94111 Ladies and Gentlemen: Bolt Biotherapeutics, Inc., a Delaware c |
|
| January 25, 2021 |
*FOIA Confidential Treatment Request* Confidential Treatment Requested by Bolt Biotherapeutics, Inc. |
|
| January 15, 2021 |
2015 Equity Incentive Plan, as amended. EX-10.2 Exhibit 10.2 BOLT BIOTHERAPEUTICS, INC. (FKA BOLT THERAPEUTICS, INC.) AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN ORIGINAL PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 20, 2015 ORIGINAL PLAN APPROVED BY THE STOCKHOLDERS: APRIL 20, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 17, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE STOCKHOLDERS: SEPTEMBER 21, 20 |
|
| January 15, 2021 |
EX-10.20 Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE (EQUITY) AGREEMENT This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD |
|
| January 15, 2021 |
S-1 Table of Contents Index to Financial Statements As filed with the U.S. Securities and Exchange Commission on January 15, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 47-2804636 (St |
|
| January 15, 2021 |
Offer Letter by and between the Registrant and Edith Perez, dated March 16, 2020. EX-10.13 Exhibit 10.13 Randall C. Schatzman, Ph.D. Chief Executive Officer and Board Director Bolt Biotherapeutics March 16, 2020 Edith A. Perez, M.D. Dear Edith: Bolt is pleased to offer you a position with Bolt Biotherapeutics, Inc. (the “Company”). If you decide to join us, the terms of your employment will be as follows: Title: Chief Medical Officer Supervisor: Chief Executive Officer Offer Ex |
|
| January 15, 2021 |
EX-10.1 Exhibit 10.1 BOLT BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 26, 2020 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. REGISTRATION RIGHTS 5 2.1 Demand Registration 5 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 10 2.8 Indemnification |
|
| January 15, 2021 |
Offer Letter by and between the Registrant and Grant Yonehiro, dated October 26, 2016. EX-10.14 Exhibit 10.14 BOLT BIOTHERAPEUTICS, INC. October 26, 2016 Grant Yonehiro Dear Grant, I am pleased to offer you a position with Bolt Biotherapeutics, Inc. (the “Company”), as its Chief Business Officer. If you decide to join us, you will receive a yearly salary of $250,000.00, which will be paid semi-monthly in accordance with the Company’s normal payroll procedures. In addition, you will |
|
| January 15, 2021 |
EX-10.3 Exhibit 10.3 OPTION GRANT NO. NOTICE OF STOCK OPTION GRANT BOLT THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN The Optionee named below (“Optionee”) has been granted an option (this “Option”) to purchase shares of Common Stock, $0.00001 par value per share (the “Common Stock”), of Bolt Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to the Company’s 2015 Equity Incentiv |
|
| January 15, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BOLT BIOTHERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Bolt Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIF |
|
| January 15, 2021 |
Amended and Restated Bylaws of the Registrant, as currently in effect. EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF BOLT BIOTHERAPEUTICS, INC. (A DELAWARE CORPORATION) BYLAWS OF BOLT BIOTHERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. Section 2. Other Offices. The corporation may also have and maintain an off |
|
| January 15, 2021 |
Offer Letter by and between the Registrant and David Dornan, dated November 29, 2017. EX-10.12 Exhibit 10.12 November 29, 2017 Dear David: Bolt is pleased to offer you a position with Bolt Biotherapeutics, Inc. (the “Company”), as its Senior Vice President of Research. If you decide to join us, you will receive an annualized salary of two hundred fifty thousand dollars ($250,000) (equivalent to twenty thousand eight hundred thirty-three dollars ($20,833) monthly) which will be paid |
|
| January 15, 2021 |
Severance Agreement by and between the Registrant and Grant Yonehiro, dated January 26, 2017. EX-10.15 Exhibit 10.15 January 26, 2017 Grant Yonehiro Dear Grant: I am pleased to offer you certain severance benefits upon a qualifying termination of your employment with Bolt Biotherapeutics, Inc. (the “Company”) on the terms described in this letter agreement (the “Letter”) and the attached Appendix A (which is incorporated by reference and is made part of this Letter). Unless otherwise defin |
|
| January 15, 2021 |
EX-10.8 Exhibit 10.8 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company” or “Bolt”), and (“Indemnitee”). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s amended and restat |
|
| January 15, 2021 |
EX-10.18 Exhibit 10.18 CONSENT TO SUBLEASE AGREEMENT THIS CONSENT TO SUBLEASE AGREEMENT (this “Agreement”) is made as of June 14, 2019, by and among HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), ARMO BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Subtenant”). R E C I T A L S A. Reference is hereby made t |
|
| January 15, 2021 |
Offer Letter by and between the Registrant and William Quinn, dated April 14, 2020. EX-10.11 Exhibit 10.11 Randall C. Schatzman, Ph.D. Chief Executive Officer and Board Director Bolt Biotherapeutics April 14, 2020 William Quinn Dear William: Bolt is pleased to offer you a position with Bolt Biotherapeutics, Inc. (the “Company”). If you decide to join us, the terms of your employment will be as follows: Title: Chief Financial Officer Supervisor: Chief Executive Officer Offer Expir |
|
| January 15, 2021 |
Form of common stock certificate of the Registrant. EX-4.1 Exhibit 4.1 NUMBER BB BOLT BIOTHERAPEUTICS SHARES CUSIP 097702 10 4 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.00001 PAR VALUE PER SHARE, OF BOLT BIOTHERAPEUTICS, INC. transferable on the books of the Corporation in person or by duly a |
|
| January 15, 2021 |
EX-10.19 Exhibit 10.19 BRITANNIA SEAPORT CENTRE LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”). SUMMARY OF BASIC LEASE INFORMATION TERMS OF |
|
| January 15, 2021 |
Form of Warrant to Purchase Common Stock. EX-10.9 Exhibit 10.9 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQU |
|
| January 15, 2021 |
EX-10.21 Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE AGREEMENT This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UN |
|
| January 15, 2021 |
Sublease Agreement by and between the Registrant and Armo Biosciences, Inc., dated April 18, 2019. EX-10.17 Exhibit 10.17 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the “Sublease”) is made and entered into as of the 18th day of April, 2019 by and between ARMO BIOSCIENCES, INC., a Delaware corporation (“Sublandlord”) and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Subtenant”), all with respect to the following: RECITALS WHEREAS, HCP LS REDWOOD CITY, LLC, a Delaware limited partnership |
|
| January 15, 2021 |
EX-10.16 Exhibit 10.16 LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND BOLT BIOTHERAPEUTICS, INC. (TENANT) SEAPORT CENTRE Redwood City, California TABLE OF CONTENTS Page ARTICLE ONE BASIC LEASE PROVISIONS 1 1.01 BASIC LEASE PROVISIONS 1 1.02 ENUMERATION OF EXHIBITS & RIDER(S) 3 1.03 DEFINITIONS 3 ARTICLE TWO PREMISES, TERM, FAILURE TO GIVE POSSESSION, COMMON AREAS AND PARKING 9 2. |
|
| January 15, 2021 |
Offer of Employment by and between the Registrant and Randall C. Schatzman, dated June 10, 2019. EX-10.10 Exhibit 10.10 June 10, 2019 Randall C. Schatzman Re: Offer of Employment by Bolt Biotherapeutics, Inc. Dear Randy: I am very pleased to offer you employment with BOLT BIOTHERAPEUTICS, INC. (the “Company”). On and following your Start Date (as defined below), you will report to the Board of Directors of the Company (the “Board”) in the position of Chief Executive Officer. Following your St |
|
| January 15, 2021 |
EX-10.23 Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. MASTER SERVICES AGREEMENT This Master Services Agreement (together with all signed Statement(s) o |
|
| January 15, 2021 |
Supply Agreement by and between the Registrant and EirGenix, Inc., dated March 10, 2019. EX-10.22 Exhibit 10.22 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. SUPPLY AGREEMENT This Supply Agreement (the “Agreement”) is made and entered into as of March 10, |
|
| January 15, 2021 |
Amended and Restated Bylaws of the Registrant, as currently in effect. EX-3.3 Exhibit 3.3 BOLT THERAPEUTICS, INC. a Delaware Corporation BYLAWS As Adopted January 22, 2015 BOLT THERAPEUTICS, INC. a Delaware Corporation BYLAWS As Adopted January 22, 2015 ARTICLE I: STOCKHOLDERS Section 1.1: Annual Meetings. Unless members of the Board of Directors of the Corporation (the “Board”) are elected by written consent in lieu of an annual meeting, as permitted by Section 211 |
|
| January 15, 2021 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BOLT BIOTHERAPEUTICS, INC. Randall C. Schatzman, Ph.D. hereby certifies that: ONE: The original name of this corporation is Bolt Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was January 22, 2015. TWO: He is the duly |
|
| January 15, 2021 |
Severance and Change in Control Plan. EX-10.24 Exhibit 10.24 BOLT BIOTHERAPEUTICS, INC. SEVERANCE AND CHANGE IN CONTROL PLAN APPROVED BY THE BOARD OF DIRECTORS: , 2021 Section 1. INTRODUCTION. The Bolt Biotherapeutics, Inc. Severance and Change in Control Plan (the “Plan”) is hereby established effective upon the IPO Date (as defined below). The purpose of the Plan is to provide for the payment of severance and/or Change in Control (a |
|
| January 11, 2021 |
As confidentially submitted to the U.S. Securities and Exchange Commission on January 11, 2021. DRS/A 1 filename1.htm Table of Contents Index to Financial Statements As confidentially submitted to the U.S. Securities and Exchange Commission on January 11, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BOLT BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its ch |
|
| January 11, 2021 |
John T. McKenna +1 650 843 5059 [email protected] VIA EDGAR January 11, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 ATTN: Mr. Donald Field Ms. Sonia Bednarowski Ms. Kristin Lochhead Mr. Daniel Gordon Re: Bolt Biotherapeutics, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted August 10, 2020 CIK No |
|
| January 11, 2021 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE (EQUITY) AGREEMENT This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UN |
|
| January 11, 2021 |
Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| January 11, 2021 |
EX-10.21 5 filename5.htm Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE AGREEMENT This Agreement between THE BOARD OF TRUSTEES OF THE LELAND ST |
|
| January 11, 2021 |
Additional abbreviations may also be used though not in the above list. EX-4.1 2 filename2.htm Exhibit 4.1 NUMBER BB BOLT BIOTHERAPEUTICS SHARES CUSIP 097702 10 4 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.00001 PAR VALUE PER SHARE, OF BOLT BIOTHERAPEUTICS, INC. transferable on the books of the Corporation in per |
|
| September 11, 2020 |
| www.boltbio.com | 900 Chesapeake Drive | Redwood City | CA | 94063 | confidential Exhibit 10.11 Randall C. Schatzman, Ph.D. Chief Executive Officer and Board Director Bolt Biotherapeutics April 14, 2020 William Quinn Dear William: Bolt is pleased to offer you a position with Bolt Biotherapeutics, Inc. (the ?Company?). If you decide to join us, the terms of your employment will be as follows: Title: Chief Financial Officer Supervisor: Chief Executive Officer Offer Expiration: Th |
|
| September 11, 2020 |
Exhibit 10.10 June 10, 2019 Randall C. Schatzman Re: Offer of Employment by Bolt Biotherapeutics, Inc. Dear Randy: I am very pleased to offer you employment with BOLT BIOTHERAPEUTICS, INC. (the ?Company?). On and following your Start Date (as defined below), you will report to the Board of Directors of the Company (the ?Board?) in the position of Chief Executive Officer. Following your Start Date, |
|
| September 11, 2020 |
Exhibit 10.16 LEASE BETWEEN METROPOLITAN LIFE INSURANCE COMPANY (LANDLORD) AND BOLT BIOTHERAPEUTICS, INC. (TENANT) SEAPORT CENTRE Redwood City, California TABLE OF CONTENTS Page ARTICLE ONE BASIC LEASE PROVISIONS 1 1.01 BASIC LEASE PROVISIONS 1 1.02 ENUMERATION OF EXHIBITS & RIDER(S) 3 1.03 DEFINITIONS 3 ARTICLE TWO PREMISES, TERM, FAILURE TO GIVE POSSESSION, COMMON AREAS AND PARKING 9 2.01 LEASE |
|
| September 11, 2020 |
Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. MASTER SERVICES AGREEMENT This Master Services Agreement (together with all signed Statement(s) of Work an |
|
| September 11, 2020 |
BOLT THERAPEUTICS, INC. a Delaware Corporation As Adopted January 22, 2015 Exhibit 3.3 BOLT THERAPEUTICS, INC. a Delaware Corporation BYLAWS As Adopted January 22, 2015 BOLT THERAPEUTICS, INC. a Delaware Corporation BYLAWS As Adopted January 22, 2015 ARTICLE I: STOCKHOLDERS Section 1.1: Annual Meetings. Unless members of the Board of Directors of the Corporation (the ?Board?) are elected by written consent in lieu of an annual meeting, as permitted by Section 211 of the |
|
| September 11, 2020 |
Exhibit 10.2 BOLT BIOTHERAPEUTICS, INC. (FKA BOLT THERAPEUTICS, INC.) AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN ORIGINAL PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 20, 2015 ORIGINAL PLAN APPROVED BY THE STOCKHOLDERS: APRIL 20, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 17, 2016 AMENDED AND RESTATED PLAN ADOPTED BY THE STOCKHOLDERS: SEPTEMBER 21, 2016 AMEND |
|
| September 11, 2020 |
BOLT BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT June 26, 2020 Exhibit 10.1 BOLT BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT June 26, 2020 TABLE OF CONTENTS Page 1. DEFINITIONS 1 2. REGISTRATION RIGHTS 5 2.1 Demand Registration 5 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 10 2.8 Indemnification 10 2.9 R |
|
| September 11, 2020 |
NOTICE OF STOCK OPTION GRANT BOLT THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN Exhibit 10.3 OPTION GRANT NO. NOTICE OF STOCK OPTION GRANT BOLT THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN The Optionee named below (?Optionee?) has been granted an option (this ?Option?) to purchase shares of Common Stock, $0.00001 par value per share (the ?Common Stock?), of Bolt Therapeutics, Inc., a Delaware corporation (the ?Company?), pursuant to the Company?s 2015 Equity Incentive Plan, |
|
| September 11, 2020 |
Exhibit 10.9 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS |
|
| September 11, 2020 |
Exhibit 10.15 January 26, 2017 Grant Yonehiro Dear Grant: I am pleased to offer you certain severance benefits upon a qualifying termination of your employment with Bolt Biotherapeutics, Inc. (the ?Company?) on the terms described in this letter agreement (the ?Letter?) and the attached Appendix A (which is incorporated by reference and is made part of this Letter). Unless otherwise defined in thi |
|
| September 11, 2020 |
Exhibit 10.12 November 29, 2017 Dear David: Bolt is pleased to offer you a position with Bolt Biotherapeutics, Inc. (the ?Company?), as its Senior Vice President of Research. If you decide to join us, you will receive an annualized salary of two hundred fifty thousand dollars ($250,000) (equivalent to twenty thousand eight hundred thirty-three dollars ($20,833) monthly) which will be paid semi-mon |
|
| September 11, 2020 |
Exhibit 10.19 BRITANNIA SEAPORT CENTRE LEASE This Lease (the ?Lease?), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the ?Summary?), below, is made by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (?Landlord?), and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (?Tenant?). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE DE |
|
| September 11, 2020 |
Exhibit 10.17 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (the ?Sublease?) is made and entered into as of the 18th day of April, 2019 by and between ARMO BIOSCIENCES, INC., a Delaware corporation (?Sublandlord?) and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (?Subtenant?), all with respect to the following: RECITALS WHEREAS, HCP LS REDWOOD CITY, LLC, a Delaware limited partnership (?Master |
|
| September 11, 2020 |
EX-10.18 16 filename16.htm Exhibit 10.18 CONSENT TO SUBLEASE AGREEMENT THIS CONSENT TO SUBLEASE AGREEMENT (this “Agreement”) is made as of June 14, 2019, by and among HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), ARMO BIOSCIENCES, INC., a Delaware corporation (“Tenant”), and BOLT BIOTHERAPEUTICS, INC., a Delaware corporation (“Subtenant”). R E C I T A L S A. Referenc |
|
| September 11, 2020 |
Exhibit 10.13 Randall C. Schatzman, Ph.D. Chief Executive Officer and Board Director Bolt Biotherapeutics March 16, 2020 Edith A. Perez, M.D. Dear Edith: Bolt is pleased to offer you a position with Bolt Biotherapeutics, Inc. (the ?Company?). If you decide to join us, the terms of your employment will be as follows: Title: Chief Medical Officer Supervisor: Chief Executive Officer Offer Expiration: |
|
| September 11, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BOLT BIOTHERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Bolt Biotherapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. T |
|
| September 11, 2020 |
BOLT BIOTHERAPEUTICS, INC. October 26, 2016 Exhibit 10.14 BOLT BIOTHERAPEUTICS, INC. October 26, 2016 Grant Yonehiro Dear Grant, I am pleased to offer you a position with Bolt Biotherapeutics, Inc. (the ?Company?), as its Chief Business Officer. If you decide to join us, you will receive a yearly salary of $250,000.00, which will be paid semi-monthly in accordance with the Company?s normal payroll procedures. In addition, you will be eligib |
|
| September 11, 2020 |
As confidentially submitted to the U.S. Securities and Exchange Commission on September 10, 2020. Table of Contents Index to Financial Statements As confidentially submitted to the U. |
|
| September 10, 2020 |
John T. McKenna +1 650 843 5059 [email protected] VIA EDGAR September 10, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 ATTN: Mr. Donald Field Ms. Sonia Bednarowski Ms. Kristin Lochhead Mr. Daniel Gordon Re: Bolt Biotherapeutics, Inc. Draft Registration Statement on Form S-1 Submitted August 10, 2020 CIK No. 0001641281 Ladi |
|
| August 10, 2020 |
As confidentially submitted to the U.S. Securities and Exchange Commission on August 10, 2020. Table of Contents Index to Financial Statements As confidentially submitted to the U. |
